Tvardi Therapeutics, Inc. (TVRD)
| Market Cap | 37.53M -83.9% |
| Revenue (ttm) | n/a |
| Net Income | -15.44M |
| EPS | -2.48 |
| Shares Out | 9.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,516 |
| Open | 3.880 |
| Previous Close | 3.960 |
| Day's Range | 3.853 - 4.050 |
| 52-Week Range | 2.750 - 43.650 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 27.60 (+590.0%) |
| Earnings Date | May 8, 2026 |
About TVRD
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for TVRD stock is "Buy." The 12-month stock price target is $27.6, which is an increase of 590.00% from the latest price.
News
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
Imran Alibhai, Chief Executive Officer of Tvardi, stated, “We are approaching a key inflection point with topline data from our next-generation STAT3 inhibitor, TTI-109, expected in June. These result...
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatoce...
Tvardi Therapeutics files $200M mixed securities shelf
16:07 EDT Tvardi Therapeutics (TVRD) files $200M mixed securities shelf
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Tvardi Therapeutics (TVRD) to Underweight from Equal Weight with a price target of $3, down from $4. The company’s funding overhang makes the story “incrementally more challenged” ...
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule th...
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
Piper Sandler lowered the firm’s price target on Tvardi Therapeutics (TVRD) to $3 from $4 and keeps a Neutral rating on the shares. At Q4/FY25 earnings, Tvardi reiterated TTI-109’s Phase…
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
Barclays lowered the firm’s price target on Tvardi Therapeutics (TVRD) to $4 from $5 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post…
Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)
Cash, cash equivalents and short-term investments as of December 31, 2025, were $30.8M, as compared to $31.6M as of December 31, 2024. Tvardi anticipates that its current cash runway is…
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026 Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) are anticipated in H...
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
Lucid Capital upgraded Tvardi Therapeutics (TVRD) to Buy from Neutral with a $6 price target The firm finds the stock undervalued at current levels. Lucid’s model suggests TTI-101 in hepatocellular…
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Presentation Company to Highlight New Data from Phase 2 REVERT IPF Clinical Trial of TTI-101 in Podium Present...
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
Tvardi Therapeutics (TVRD) provided further updates from its Phase 2 REVERT IPF clinical trial of TTI-101 in idiopathic pulmonary fibrosis, IPF. Preliminary results were announced on October 13, 2025....
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...
Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)
Cash, cash equivalents and short-term investments as of September 30, 2025, were $36.5 million, as compared to $31.6 million as of December 31, 2024. Tvardi anticipates that its current cash…
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small...
Tvardi downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Tvardi Therapeutics (TVRD) to Market Perform from Outperform without a price target The firm believes many open questions remain regarding TTI-101 following the unsuccessful R...
Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Tvardi Therapeutics (TVRD) to Equal Weight from Overweight with a price target of $5, down from $61, following the company’s “surprisingly negative” preliminary data from the Phase...
Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’
As previously reported, Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight after the company provided an update on preliminary data from the Phase 2 REVERT clinical tri...
Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight.
Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight with a price target of $4, down from $78. The firm, which had expectations for clean safety…
Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?
Tvardi Therapeutics stock dove after the company reported results from a recent clinical trial.
Tvardi says benefit of TTI-101 treatment not observed in REVERT trial
Tvardi Therapeutics (TVRD) provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. Overall, 88 patients were randomized to TTI-101 40...
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...
Tvardi Therapeutics initiated with an Overweight at Barclays
Barclays analyst Etzer Darout initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $61 price target The firm launched coverage of eight companies across inflammation and immu...